Oxford Biomedica, (OXB),...............time to buy.

FT

US Pharmaceuticals. "Several factors are coming together to create the biggest threat to industry growth for a decade. Market expectations of double-digit revenue increases, and 12-15 per cent earnings growth, looked stretched in any case. One problem is a dearth of exciting products set to pop out of research and development pipelines. Other elements could penalise that weakness." Full text


Pricing pressure. "Lopping a couple of percentage points off US price growth could make it much more difficult for all drugs companies to meet market forecasts. That task is made even harder by the fact that many are about to lose chunks of their existing revenues